Tim Friede

3 weeks ago | jamanetwork.com | Stefan Anker |Campus Virchow Klinikum |Tim Friede |Javed Butler

Visual Abstract. Efficacy and safety of ferric carboxymaltose in patients with heart failure and iron deficiency Figure 1.  Recruitment, Randomization, and Follow-Up in the FAIR-HF2 Trial FAIR-HF2 indicates Intravenous Iron in Patients with Systolic Heart Failure and Iron Deficiency to Improve Morbidity and Mortality. aThe precise reasons are unknown.

2 months ago | onlinelibrary.wiley.com | Stefan Anker |Tim Friede |Javed Butler |Baylor Scott

Introduction Iron deficiency (ID) is known to impair mitochondrial energy production and cause adverse cardiac remodelling leading to left ventricular dysfunction.1-4 ID is prevalent in up to 50% of patients with heart failure (HF) and is an independently associated with worse functional status, symptoms, and cardiovascular outcomes irrespective of anaemia.5, 6 The FAIR-HF (Ferinject Assessment in Patients with Iron Deficiency and Chronic Heart Failure) trial was the first major trial of...

Sep 2, 2024 | onlinelibrary.wiley.com | Christian Röver |Tim Friede

1 Introduction In drug licensing, evidence from several independent sources is often required to demonstrate efficacy and safety of novel treatments (The European Agency for the Evaluation of Medicinal Products (EMEA) 2001; Kennedy-Shaffer 2017). Especially in health technology assessment, meta-analysis methods are commonly applied to combine and judge evidence from several sources, for example, typically a small number of clinical trials conducted in the later development phases (Bender et al.

Aug 2, 2024 | jacc.org | Piotr Ponikowski |Tim Friede |Javed Butler |Muhammad Khan

Introduction Functional mitral regurgitation (FMR) is frequent in heart failure (HF), exacerbates HF symptoms and worsen patient outcomes.1-3 For patients with symptomatic HF and severe FMR, mitral transcatheter edge-to-edge repair (M-TEER) has emerged as a therapeutic option, however, with conflicting results.4-6 In these patients, the MITRA-FR (Percutaneous Repair with the MitraClip Device for Severe Functional/Secondary Mitral Regurgitation) trial showed no effect of M-TEER compared with...

Apr 23, 2024 | onlinelibrary.wiley.com | Stefan Anker |Tim Friede |Javed Butler |Baylor Scott

Introduction In the US ~5 million and in Europe ~10 million individuals have heart failure (HF).1 Functional mitral regurgitation (FMR) is frequently present in patients with HF and is a marker of worse prognosis.1 Mitral regurgitation (MR) results in worsening dyspnoea and contributes to progressive left ventricular (LV) dilatation.2 Anatomical changes in FMR are determinants of progression, with an average annual increase of 5–8 ml in regurgitant volume and 4–6 mm2 in the effective...